Solid-phase Oligonucleotide Synthesis Route Development
Solid-phase oligonucleotide synthesis route development focuses on establishing and optimizing the chemical synthesis route used to produce oligonucleotide drug substances. The development process considers the characteristics of the target oligonucleotide, including sequence, length, backbone chemistry, nucleotide modifications, and terminal groups, as well as the requirements for synthesis efficiency, impurity control, reproducibility, and scale-up. A well-defined synthesis route provides an important foundation for subsequent oligonucleotide process development, drug substance development, and manufacturing. Protheragen provides Solid-phase Oligonucleotide Synthesis Route Development services covering route feasibility assessment, solid-support and building-block selection, coupling condition optimization, capping, oxidation or sulfurization, cleavage and deprotection, synthesis-related impurity control, and scale-up evaluation.
Overview of Solid-phase Oligonucleotide Synthesis Route Development
Solid-phase oligonucleotide synthesis is a stepwise chemical synthesis process in which nucleotide building blocks are sequentially assembled on a solid support to generate an oligonucleotide chain. A typical synthesis cycle includes nucleotide coupling, capping of unreacted sites, and oxidation or sulfurization, followed by repetition of the cycle until the desired sequence is assembled. The completed oligonucleotide is subsequently cleaved from the solid support and subjected to deprotection and downstream purification.
The development of a solid-phase synthesis route involves evaluating the chemical and process conditions that influence synthesis efficiency, product quality, impurity formation, and reproducibility. Factors such as nucleotide sequence and length, solid-support loading, building-block chemistry, coupling efficiency, reaction conditions, backbone or sugar modifications, cleavage and deprotection conditions, and the characteristics of process-related impurities may all affect the overall synthesis process. Appropriate route development therefore aims to establish synthesis conditions that provide consistent chain assembly while supporting effective impurity control and downstream purification.
For oligonucleotide drug development, route selection also needs to consider scalability and manufacturing requirements. A synthesis process established at laboratory scale may require further evaluation when transferred to larger-scale equipment because reagent handling, mixing, reaction concentration, heat transfer, and material loading can influence process performance. Solid-phase synthesis route development therefore provides an important technical foundation for subsequent oligonucleotide CMC process development, drug substance development, process scale-up, and manufacturing.
Fig.1 Mechanism of action of antisense oligonucleotides (ASOs). (Depienne S, et al., 2026)
Our Services
From early feasibility studies to manufacturing-oriented process development, Protheragen supports the systematic evaluation and optimization of solid-phase oligonucleotide synthesis routes. Our development approach considers both chemical performance and downstream manufacturing requirements to establish a route that is reproducible, scalable, and compatible with subsequent purification and analytical processes.
Synthesis Route Feasibility Assessment
We assess the oligonucleotide sequence, chemical structure, modification pattern, and production requirements to identify potential synthesis challenges and establish an appropriate solid-phase synthesis strategy.
Services include:
- Sequence and structure assessment
- Synthesis route feasibility evaluation
- Modification and impurity risk assessment
- Solid-phase synthesis strategy selection
Solid Support and Starting Material Evaluation
We evaluate solid supports, phosphoramidites or other building blocks, protecting groups, and synthesis reagents based on their compatibility with the target oligonucleotide and selected synthesis route.
Services include:
- Solid support selection
- Building block evaluation
- Protecting group assessment
- Reagent compatibility evaluation
Coupling Efficiency Optimization
We optimize key coupling parameters to improve nucleotide incorporation and minimize incomplete coupling and truncated sequence formation during iterative synthesis cycles.
Services include:
- Coupling condition optimization
- Reagent equivalent evaluation
- Reaction time and concentration optimization
- Activation condition assessment
Capping and Oxidation / Sulfurization Optimization
We optimize capping and backbone conversion steps to improve reaction completion and control process-related impurities while maintaining compatibility with the oligonucleotide structure.
Services include:
- Capping condition optimization
- Oxidation or sulfurization optimization
- Reaction completion assessment
- Modification compatibility evaluation
Chemical Modification Compatibility Assessment
We evaluate how backbone, sugar, terminal, and other chemical modifications may affect synthesis efficiency, reaction completion, impurity formation, cleavage, and deprotection.
Services include:
- Phosphorothioate modification assessment
- 2′-modified nucleotide evaluation
- Terminal modification compatibility
- Modification-related impurity assessment
Cleavage and Deprotection Development
We develop cleavage and deprotection conditions to efficiently release the oligonucleotide from the solid support while maintaining product integrity and controlling potential degradation or side reactions.
Services include:
- Cleavage condition evaluation
- Deprotection strategy development
- Reagent and temperature optimization
- Product recovery assessment
Impurity Control and Synthesis Optimization
We evaluate synthesis-related impurities and their potential sources to optimize the overall synthesis process and establish a cleaner crude oligonucleotide profile for downstream purification.
Services include:
- Truncated and failure sequence assessment
- Process-related impurity evaluation
- Synthesis parameter optimization
- Crude product quality improvement
Process Scale-up Assessment
We evaluate scale-dependent factors to support the transition of an established oligonucleotide synthesis route from laboratory development toward larger-scale production and GMP manufacturing.
Services include:
- Scale-dependent process evaluation
- Equipment and material handling assessment
- Mixing and reaction condition evaluation
- Pilot and manufacturing scale-up support
Key Parameters in Solid-phase Oligonucleotide Synthesis Development
The performance of a solid-phase synthesis route is influenced by multiple interconnected process parameters. Protheragen considers these parameters collectively rather than optimizing individual synthesis steps in isolation.
| Development Area |
Key Parameters |
Development Objective |
| Solid Support |
Support type, loading, particle characteristics |
Establish an appropriate synthesis platform |
| Coupling |
Reagent equivalents, concentration, reaction time, activation conditions |
Improve coupling efficiency and consistency |
| Capping |
Reagent system, reaction time, conversion |
Reduce failure-sequence formation |
| Oxidation / Sulfurization |
Reagent system, reaction conditions, reaction completion |
Achieve consistent backbone conversion |
| Deprotection |
Reagent, temperature, time, reaction conditions |
Achieve effective deprotection while protecting product integrity |
| Cleavage |
Cleavage reagent, temperature, reaction time |
Efficiently release oligonucleotide from solid support |
| Impurity Control |
Truncated sequences, modified species, process-related impurities |
Improve crude product quality |
| Scale-up |
Concentration, mixing, heat transfer, material handling |
Establish a scalable and reproducible route |
Process Development Considerations for Oligonucleotide Synthesis
An effective synthesis route should not be evaluated solely on the basis of laboratory yield. Manufacturing-oriented development also considers process robustness, impurity profiles, downstream purification, analytical control, scalability, and the requirements of subsequent GMP production.
Key considerations include:
- Sequence length and nucleotide composition
- Backbone and sugar modifications
- Terminal modifications and conjugation sites
- Coupling efficiency across synthesis cycles
- Formation of truncated and other process-related impurities
- Cleavage and deprotection compatibility
- Crude product quality
- Purification requirements
- Analytical method compatibility
- Process reproducibility
- Scale-up and technology transfer considerations
Early evaluation of these factors can help reduce process development risks and provide a stronger foundation for subsequent Oligonucleotide CMC Process Development and API manufacturing.
Solid-phase Synthesis for Different Oligonucleotide Modalities
Solid-phase synthesis requirements can vary considerably among different oligonucleotide drug classes. Protheragen develops synthesis strategies according to the chemical and manufacturing characteristics of individual candidates.
Antisense Oligonucleotides (ASOs)
ASO synthesis may involve chemically modified nucleotides and backbone modifications designed to improve stability and pharmacological properties. Route development focuses on maintaining efficient sequential coupling while controlling truncated and modified impurities.
Small Interfering RNAs (siRNAs)
siRNA production generally involves the preparation of two complementary oligonucleotide strands, with each strand potentially containing different sequence and modification characteristics. Synthesis route development considers strand-specific chemistry, modification compatibility, impurity control, and subsequent product assembly requirements.
Phosphorodiamidate Morpholino Oligomers (PMOs)
PMOs have a distinctive backbone chemistry compared with conventional phosphodiester or phosphorothioate oligonucleotides. Their synthesis route requires consideration of the specific monomer chemistry, coupling strategy, cleavage and deprotection conditions, and scale-up requirements.
CpG Oligonucleotides
CpG oligonucleotides can contain specific sequence motifs and chemical modifications associated with their intended biological applications. Synthesis development focuses on reproducible chain assembly, impurity control, and manufacturing scalability according to the target product profile.
Why Choose Protheragen
- Oligonucleotide-focused Process Expertise
Protheragen's oligonucleotide process development services are designed around the specific chemical and manufacturing characteristics of nucleic acid therapeutics, rather than applying a generic small-molecule development approach.
- Integrated Synthesis and Process Development
Solid-phase synthesis route development can be coordinated with downstream purification, analytical development, CMC development, and manufacturing activities, helping minimize process gaps during later development stages.
- Modality-specific Development Strategies
Synthesis strategies can be adapted for ASOs, siRNAs, PMOs, CpG oligonucleotides, and chemically modified or conjugated oligonucleotide candidates according to their individual molecular characteristics.
- Scale-up-oriented Development
Development activities consider scalability and manufacturing requirements from an early stage, supporting the transition from laboratory-scale synthesis to pilot and GMP production.
- Manufacturing-focused Process Optimization
The objective is not simply to obtain an oligonucleotide product at laboratory scale, but to establish a practical synthesis route with appropriate process performance, impurity control, reproducibility, and scalability.
A well-designed solid-phase synthesis route provides the chemical foundation for subsequent oligonucleotide process development and manufacturing. By systematically evaluating synthesis chemistry, reaction conditions, impurity formation, cleavage and deprotection, and scale-up considerations, Protheragen helps clients establish reproducible synthesis processes aligned with downstream purification, analytical, CMC, and manufacturing requirements. Whether the project involves an early-stage oligonucleotide candidate or a program progressing toward GMP manufacturing, our solid-phase oligonucleotide synthesis route development services can be tailored to the molecule, development stage, and target production scale. Contact us to discuss your oligonucleotide synthesis route development requirements and establish a development strategy for your next nucleic acid drug program.
Reference
- Depienne S, et al. "Oligonucleotides Post-Synthetic Modifications: An Overview of Clickable Nucleoside Phosphoramidites Suitable for Solid-Phase Synthesi." ChemBioChem, 2026; 27(13):e70347.
